SEC Form 4 · accession 0001193125-26-389333
Tyra Biosciences, Inc. · TYRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rehan Verjee
Director
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001863127
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 9, 2026 | P | 972 | $20.5784 | A | 972 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $20.5550 to $20.6488. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.